Allergy Diagnostics Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global allergy diagnostics market growth forecasted to transform from USD 5.3 billion in 2024 to USD 9.8 billion by 2029, driven by a CAGR of 11.0%. The market will grow as a result of rising investments in allergy research, a rise in hospitals offering allergy diagnosis services, and an ongoing rise in allergies brought on by dust and mites in homes. However, factors that are anticipated to hinder the growth of this market during the projected period include the lack of knowledge about allergy disorders and symptoms as well as problems with the cost of instruments for small laboratories and clinics.

Allergy Diagnostics Market – Global Forecast and Growth Insights to 2029

To know about the assumptions considered for the study, Request for Free Sample Report

Allergy Diagnostics Market – Global Forecast and Key Opportunities to 2029

Allergy Diagnostics Market Dynamics to 2029

DRIVER: High incidence and heavy economic burden of allergic diseases

The important step in the treatment of patients suffering from allergic diseases is the allergy diagnosis. Asthma, rhinitis, angioedema, urticaria, conjunctivitis, and eczema are considered as the major allergic diseases. Additionally, across the globe, conditions such as food allergies and drug & insect allergies also affect many people. Allergies and related diseases have continued to be prevalent for more than 50 years in the industrialized world, globally. According to data from CDC’s (June 2023) National Center for Health Statistics. 27.2% of children show allergy symptoms, and 31.8% of adults, which tallies over 100 million people. The allergy cases witnessed to be high among children; sensitization rates to one or more common allergens among school children are currently approaching 40%-50%

RESTRAINT: High pricing of allergy diagnostic instruments

Key market players periodically update several Allergy Diagnostics instruments, such as luminometers, blot analyzers, scanners, ELISA analyzers, and immunoassay analyzers. These are priced at a premium (the price of each instrument varies based on its accuracy, flexibility, and TAT), as these instruments are equipped with advanced features and functionalities. For instance, Phadia 2500+ by Thermo Fisher Scientific, Inc. (US) costs USD 1,185,895, IMMULITE 2000 xpi by Siemens costs USD 20,953.8, while luminometers cost USD 3,000 and USD 14,000. Semi-automated ELISA readers cost USD 2,000 and USD 5,000, while fully automated analyzers cost around USD 14,000. Furthermore, an additional expense required to operate this equipment for maintenance and insurance, laboratory supervision, and overheads (including utilities, space, and administration).

OPPORTUNITY: Integration of AI in allergy diagnosis

In the area of data science, artificial intelligence (AI) refers to sophisticated computational devices that can interact with humans and learn from data. Early diagnosis, self-care, wellness and prevention, clinical decision support, care delivery, and chronic care management are just a few of the healthcare domains where AI may be useful. The most recent advancements in AI methodology have opened up new avenues for defining the patient-to-patient heterogeneity of allergic disorders, as discovered in paediatric allergy research.

CHALLENGE: Shortage of allergists

General practitioners could not manage the diagnosis and treatment of allergic disorders such as asthma, rhinitis, food allergies, urticaria and others is multi-faceted and complicated and thus requires the prowess of a dedicated allergy specialist. For maintaining good health for people of all ages, allergists play a vital role. However, there is now a growing shortage of allergists. For instance, the leading membership organization American Academy of Allergy, Asthma & Immunology (AAAAI), includes more than 7,000 allergists / immunologists and it is the trusted resource of patients for allergies, asthma and immune deficiency disorders. Furthermore, one San Francisco study reported that there are long scheduling waits in most areas to see allergists and the mean wait times to consult an allergist of more than 60 days (Source: Barton Associates).

Allergy Diagnostics Market Map & Ecosystem Overview

Prominent companies in this market include well-established, financially stable manufacturers of Allergy Diagnostics. These companies have been operating in the market for several years and possess diversified state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include Thermo Fisher Scientific Inc., (US), Siemens Healthineers AG (Germany), Danaher (US), and Canon, Inc. (Japan) [Minaris Medical America, Inc. (US)].

In 2023, consumables segment to observe the highest growth rate of the allergy diagnostics market, by product & service.

Based on product & service, the market is segmented into consumables, instruments, and services. In 2023, the consumables segment has accounted for the largest share of the market. Rise in number of allergy cases including respiratory and food allergies mainly and the growing need for diagnosis due to awareness about allergic symptoms to drive the market of this segment during the forecast period. Consumables segment is also expected to witness significant growth during the forecast period.

In 2023, inhaled allergen segment to dominate the allergy diagnostics market, by allergen.

Based on the allergen, the market is segmented into inhaled allergen, food allergen, drug allergen, and other allergens. The inhaled allergen segment dominated the market in 2023. This segment is also estimated to account for the highest CAGR during the forecast period. The large share of this segment can be primarily attributed to the growing air pollution and increased urbanization & indoor air quality concerns resulting in exposure to indoor air pollutants such as dust mites and spores.

In 2023, Hospital-based laboratories & clinics segment to dominate the allergy diagnostics market, by end user.

Based on the end user, the market is segmented into diagnostic laboratories, hospital-based laboratories & clinics, academic research institutes, and other end users. In 2023, the hospital-based laboratories & clinics segment accounted for the largest share of the market. The large share of the segment can be primarily attributed to the collaboration with specialists, comprehensive diagnostic services, and cost efficiency.

In 2023, North america to dominate in allergy diagnostics market.

The market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate during the forecast period, primarily due to the growing availability of government funding for allergy research activities, the presence of major players in the US, presence of telemedicine & remote testing, and increased collaborations and partnerships between government and allergy associations.

Allergy Diagnostics Market by Region – Forecast to 2029

To know about the assumptions considered for the study, download the pdf brochure

The allergy diagnostics market is dominated by players such as Thermo Fisher Scientific Inc., (US), Siemens Healthineers AG (Germany), Danaher (US), Canon, Inc. (Japan), Minaris Medical America, Inc. (US), Eurofins Scientific (Luxembourg), EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (Germany), bioMérieux SA (France), Stallergenes Greer Ltd. (UK), HollisterStier Allergy (US), and Omega Diagnostics Group PLC (UK).

Allergy Diagnostics Market Report Scope and Insights

Allergy Diagnostics Market Segmentation and Analysis

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

By Type

• Consumables
• Instruments
• Services

By Test Type

• In Vivo Tests
• In Vitro Tests

By Allergen

• Inhaled Allergens
• Food Allergens
• Drug Allergens
• Other Allergens

By End User

• Hospitals-Based Laboratories & Clinics
• Diagnostic Laboratories
• Academic Research Institutes

Allergy Diagnostics Market Recent Developments and Insights

• In 2023, Canon has completed share transfer procedures with Resonac Corporation. This share transfer is intended to be used to purchase the Resonac subsidiaries Minaris Medical Co., Ltd. and Minaris Medical America, Inc. (collectively, "Minaris Medical"). After this share acquisition is finished, Minaris Medical—which runs companies that deal with automated analytical tools and in vitro diagnostic reagents—will be consolidated under Canon Medical.
• In 2023, Romer Labs Division Holding GmbH (Austria) acquired CPAK INTER Co., Ltd. (Thailand), a long-time distributor of Romer Labs solutions based in Bangkok. With the acquisition, Romer Labs has achieved yet another significant milestone in the quickly expanding Asian food safety industry.
• In 2022, The US Food & Drug Administration (FDA) has cleared ImmunoCAP Specific IgE (sIgE) Allergen Components for use in in vitro diagnostic testing for wheat and sesame allergies, according to a statement from Thermo Fisher Scientific, Inc. (US).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst